ENDPOINTS

LifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drug

Plus, news about ​​Opthea, Apollomics, LaunXP and AstraZeneca: LifeMine reduces headcount: The Boston biotech went through a “company-wide restructuring,” according to employees’ LinkedIn posts. The biotech last disclosed a $175 million Series ...

Mar 31, 2025 - 15:57
 0
LifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drug
Plus, news about ​​Opthea, Apollomics, LaunXP and AstraZeneca: LifeMine reduces headcount: The Boston biotech went through a “company-wide restructuring,” according to employees’ LinkedIn posts. The biotech last disclosed a $175 million Series ...
Read More

Tags:

Previous Article

Alphabet’s Isomorphic Labs raises $600M in biotech’s largest round of 2025 

Next Article

Trump Administration Has Begun a War on Science, Researchers Say

Related Posts

Eisai cuts Leqembi 2027 sales projections by half

Eisai cuts Leqembi 2027 sales projections by half

Mar 25, 2025  0

Why Gilead could lose its HIV product hopping case

Why Gilead could lose its HIV product hopping case

Mar 12, 2025  0

Trump think tank resurrects international drug pricing policy

Trump think tank resurrects international drug pricing ...

Mar 21, 2025  0